Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China

Abstract The results of the ETER701 trial showed that benmelstobart and anlotinib plus chemotherapy have potential advantages in the treatment of extensive small cell lung cancer (ES-SCLC). However, it must be noted that the high cost cannot be ignored. This study was designed to assess the cost-eff...

Descripció completa

Dades bibliogràfiques

Autors principals:	Chunyan Yan, Zhengxiong Li, Jiayan Li, Quan Zhao, Wenxiu Cao, Shuqing Li, Ruigang Diao
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-03-01
Col·lecció:	Scientific Reports
Matèries:	Cost-effectiveness Benmelstobart Anlotinib Extensive-stage small cell lung cancer Partitioned survival model First-line
Accés en línia:	https://doi.org/10.1038/s41598-025-91540-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!